Effective therapy is still lacking.<h4>Objective</h4>To investigate the efficacy and safety of SHR-1210 (an anti-programmed cell death-1 antibody) in combination with Apatinib (a vascular endothelial growth factor receptor 2 inhibitor) as late-line treatment in patients with advanced mucosal melanoma (Ethics approval number 2019184;ClinicalTrials.gov ID: NCT03986515).<h4>Patients and methods</h4>Patients with confirmed metastatic mucosal melanoma according to AJCC 8.0. The gene discussed is KDR; the disease is mucosal melanoma.